NIH Guide: Weekly Index for May 19, 2023

Funding Opportunities

• Emergency Medicine Research Career Development Program in the Neurological Sciences (EMRCDP-NS) (K12 - No Independent Clinical Trial Allowed)
  (PAR-23-151)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  National Institute on Drug Abuse
  Application Receipt Date(s): August 9, 2023
• NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
  (PAR-23-183)
  National Library of Medicine
  National Library of Medicine
  Office of Research on Women's Health
  Application Receipt Date(s): February 26, 2026
• Alcohol Health Services Research (R01 Clinical Trial Optional)
  (PAR-23-185)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): July 18, 2023
• Alcohol Health Services Research (R34 Clinical Trial Optional)
  (PAR-23-186)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): July 18, 2023
• Alcohol Treatment and Recovery Research (R01 Clinical Trial Required)
  (PAR-23-187)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): July 18, 2023
• Alcohol Treatment and Recovery Research (R34 Clinical Trial required)
  (PAR-23-188)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): July 18, 2023
• Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
  (PAR-23-193)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): October 3, 2023, April 3, 2024, October 3, 2024, April 3, 2025, October 3, 2025, April 3, 2026
• Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)
  (RFA-AG-24-021)
  National Institute on Aging
  Application Receipt Date(s): October 23, 2023
• Quantifying the Impact of Environmental Toxicants on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Risk in Cohort Studies (U01 Clinical Trial Not Allowed)
  (RFA-AG-24-022)
  National Institute on Aging
  Application Receipt Date(s): October 23, 2023
• Preclinical Studies to Characterize the Impact of Toxicants on Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed)
  (RFA-AG-24-023)
  National Institute on Aging
  Application Receipt Date(s): October 23, 2023
• Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)?
  (RFA-AG-24-036)
  National Institute on Aging
  Application Receipt Date(s): October 23, 2023
• Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)
  (RFA-AG-24-038)
  National Institute on Aging
  Application Receipt Date(s): October 23, 2023
• Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed)
  (RFA-AI-23-029)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
• Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed)
  (RFA-AI-23-032)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): August 25, 2023
• Patient Engagement Resource Centers to Inform SUD Treatment Services Research (R24 Clinical Trial Optional)
  (RFA-DA-24-016)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 02, 2023
• Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required)
  (RFA-DA-24-024)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 2, 2023
• Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)
  (RFA-DA-24-028)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 2, 2023
• Advancing Psychedelics Research for Treating Addiction (R61/R33 Basic Experimental Study with Humans Required)
  (RFA-DA-24-029)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 2, 2023
• Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Biostatistics Research Center (U01 Clinical Trial Not Allowed)
  (RFA-DK-23-009)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 26, 2023
• Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors Clinical Centers (U01 Clinical Trial Not Allowed)
  (RFA-DK-23-010)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 26, 2023
• Specialized Centers for Research on Health Disparities in Uterine Leiomyoma (SCHDUL) (P50 Clinical Trial Not Allowed)
  (RFA-HD-24-005)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Office of Research on Women's Health
  Application Receipt Date(s): August 7, 2023
• Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional)
  (RFA-NS-23-027)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
• Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed)
  (RFA-NS-24-003)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): July 28, 2023
• Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)
  (RFA-NS-24-010)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): September 08, 2023